Yes, Wegovy (semaglutide 2.4 mg) can cause headaches as a recognised adverse effect
Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight, according to Lillys announcement
Current evidence suggests that while delayed gastric emptying is a genuine pharmacologic effect, the absolute risk of serious aspiration-related complications may be lower than initially feared, particularly among stable patients without gastrointestinal symptoms
Bloomberg reported that Aspen sees GLP1s as a durable long-term growth driver and that Stephen Saad expects semaglutide generics to attract 12 to 15 manufacturers, with intensifying price competition
Your healthcare provider can explain the pros and cons of each option and recommend one that fits your budget
RNA helicase LGP2 negatively regulates RIG-I signaling by preventing TRIM25-mediated caspase activation and recruitment domain ubiquitination